IDP-023 + daratumumab + interleukin-2

IDP-023 + daratumumab + interleukin-2 is an investigational combination therapy comprising three components: - **IDP-023**, a g-NK (gamma natural killer) cell therapy developed by Indapta Therapeutics, consists of a rare subset of NK cells that lack FcεR1γ protein, arising from CMV-driven epigenetic changes. These g-NK cells exhibit enhanced cytotoxicity and immune cytokine release compared to conventional NK cells, targeting and killing HLA-E-expressing autoreactive T and B cells involved in autoimmune pathology such as multiple sclerosis. - **Daratumumab** is a monoclonal antibody targeting CD38, primarily used in hematologic malignancies (notably multiple myeloma), but in this context used for its ability to deplete autoreactive B cells. Its mechanisms include antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis in CD38+ cells. - **Interleukin-2 (IL-2)** is a cytokine that promotes the growth, activation, and survival of lymphocytes, including NK cells, and is included in this regimen to support the in vivo expansion and activity of g-NK cells. This combination is being evaluated primarily for the treatment of progressive forms of multiple sclerosis (primary progressive and non-active secondary progressive MS), with potential investigation in other autoimmune disorders and possibly hematologic malignancies[1][3][5].